Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2016 08:00 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline

– Company to Submit MAA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections to the EMA in Second Half of 2017 – – Phase 3 IGNITE3 Study in Complicated Urinary Tract...
November 17, 2016 08:00 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Publishes Phase 3 IGNITE1 Eravacycline Data in JAMA Surgery

WATERTOWN, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat...
November 07, 2016 08:00 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals to Present at Stifel 2016 Healthcare Conference

WATERTOWN, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
November 03, 2016 16:30 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Reports Third Quarter 2016 Financial Results and Reviews Recent Progress

WATERTOWN, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat...
October 26, 2016 08:00 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016

WATERTOWN, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced eight data presentations at IDWeek 2016, taking place October 26-30 in...
October 14, 2016 07:30 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI

Top-line IGNITE4 Data Expected in 4Q 2017 Results to Support NDA Filing for IV Eravacycline in cIAI WATERTOWN, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals,...
August 08, 2016 08:00 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference

WATERTOWN, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat...
August 04, 2016 16:52 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress

WATERTOWN, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat...
August 01, 2016 08:00 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Initiates Phase 1 Clinical Trial for TP-6076, a Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria

WATERTOWN, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the initiation of patient dosing in a phase 1 clinical trial for intravenous...
June 28, 2016 09:25 ET | Source: Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals Added to the Russell Microcap® Index

WATERTOWN, Mass., June 28, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat...